Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 40 of 41, showing 5 Applications out of 204 total, starting on record 196, ending on 200

# Protocol No Study Title Investigator(s) & Site(s)

196.

ECCT/25/04/01   PHASE 2/3 OF SII-TCV(B)
    A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY AND IMMUNE NON-INTERFERENCE OF A BIVALENT CONJUGATE VACCINE AGAINST SALMONELLA ENTERICA SEROVARS TYPHI AND PARATYPHI A IN HEALTHY INFANTS AGED 9 TO 12 MONTHS   
Principal Investigator(s)
1. WALTER OTIENO
Site(s) in Kenya
VICTORIA BIOMEDICAL RESEARCH INSTITUTE
 
View

197.

ECCT/21/06/03   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the   efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein   Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age   and older   
Principal Investigator(s)
1. PROF.ELIZABETH ANNE BUKUSI
2. MARICIANAH A ONONO
Site(s) in Kenya
1. Kenya Medical Research Institute (KEMRI) Center for Microbiology Research - Research Care and Training Program (KEMRI CMRRCTP) (Kisumu county)
2. KEMRI CCRButere County Hospital Site (Kakamega county)
3. Aga Khan University Hospital (Nairobi City county)
4. Kenya Medical Research Institute CGHR (Kisumu county)
5. Kenya Medical Research Institute (Nairobi City county)
6. KEMRI/CCR Partners in Health R&D (PHRD (Kiambu county)
7. KAVI-Institute of Clinical Research, University of Nairobi (Nairobi City county)
8. Ganjoni Clinic (Mombasa county)
9. KEMRI-UAMRD-A/K, Kombewa Clinical Research Cente (Kisumu county)
10. KEMRI/Walter Reed Project Research Center (Kericho county)
 
View

198.

ECCT/21/06/12   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the   efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein   Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age   and older   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI/Walter Reed Project Research Center (Kericho county)
3. Kenya Medical Research Institute (Kisumu county)
4. Ganjoni Clinic (Mombasa county)
5. KEMRI/CCR Partners in Health R&D (PHRD) (Nairobi City county)
6. Kenya Medical Research Institute (Nairobi City county)
7. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
8. Aga Khan University Hospital (Nairobi City county)
9. KEMRI CCR-Butere County Hospital Site (Bung\'oma county)
 
View

199.

21/06/16   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older   
Principal Investigator(s)
1. Fredrick Sawe
Site(s) in Kenya
1. Kenya Medical Research Institute, Kisumu Clinical Reseach Site (Kisumu county)
2. KEMRI/Walter Reed Project - Clinical Research Center, Kericho (Kericho county)
3. Ganjoni Clinic - University of Washington/University of Nairobi, Mombasa (Mombasa county)
4. Partners in Health Research and Development, Thika (Kiambu county)
5. KARGENO RESEARCH AND POLICY HUB (Kisumu county)
6. The Centre for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI) (Nairobi City county)
7. KEMRI-USAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
8. Moi University Clinical Research Centre (MUCRC), Chandaria Cancer and Chronic Diseases Center (CCCDC) (Uasin Gishu county)
9. Aga Khan University Hospital (Nairobi City county)
10. KEMRI CCR-Butere County Hospital Site (Kakamega county)
 
View

200.

ECCT/22/01/01   ASTEFANIA
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY   
Principal Investigator(s)
1. Mansoor Saleh
2. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View